|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01873 VIVA BIOTECH
Nominal 
0.910 +0.020 (+2.247%) Profitability Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| ROAA (%) | -1.511% | -6.620% | 3.550% | -7.697% | 21.899% |
| ROAE (%) | -3.382% | -15.958% | 8.542% | -15.275% | 26.209% |
| Return on Capital Employed (%) | -1.963% | -10.069% | 4.040% | -5.215% | 14.562% |
Margin Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Gross Profit Margin (%) | 34.257% | 34.278% | 30.939% | 43.742% | 48.249% |
| EBITDA Margin (%) | 13.994% | -4.950% | 31.134% | -34.671% | 93.991% |
| Pre-tax Profit Margin (%) | -2.596% | -19.296% | 16.525% | -51.109% | 86.958% |
| Net Profit Margin (%) | -5.387% | -22.208% | 13.666% | -55.510% | 82.299% |
Liquidity Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Current Ratio (X) | 1.324 X | 0.725 X | 2.141 X | 4.556 X | 15.000 X |
| Quick Ratio (X) | 1.155 X | 0.603 X | 1.891 X | 4.332 X | 14.883 X |
Leverage Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Total Liabilities / Total Assets(%) | 50.497% | 54.491% | 51.355% | 53.927% | 6.393% |
| Total Debt / Total Assets (%) | 25.547% | 35.639% | 32.999% | 36.417% | 2.602% |
| Net Debt / Total Assets (%) | 11.636% | 27.072% | 23.043% | 8.107% | -45.012% |
| Total Debt / Shareholders' Funds (%) | 51.607% | 88.813% | 77.068% | 90.311% | 2.780% |
| Long Term Debt / Shareholders' Funds (%) | 25.781% | 28.528% | 70.137% | 85.233% | 1.374% |
| Net Debt / Shareholders' Funds (%) | 23.506% | 67.465% | 53.816% | 20.105% | -48.086% |
| Net Cash / (Debt) ($) | (866.895M) | (2.144B) | (1.854B) | (661.059M) | 854.684M |
| Net Cash / (Debt) per share ($) | (0.401) | (1.108) | (0.958) | (0.345) | 0.547 |
| Total Debt / Capital Employed (%) | 32.172% | 53.788% | 37.295% | 40.029% | 2.706% |
| Interest Coverage Ratio (X) | 0.683 X | N/A | 2.899 X | N/A | 125.248 X |
Efficiency Analysis
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Inventory Turnover (Day) | 75.431 Day | 65.085 Day | 49.794 Day | 80.651 Day | 14.660 Day |
| Receivables Turnover (Day) | 72.250 Day | 67.158 Day | 65.071 Day | 98.984 Day | 61.557 Day |
| Payables Turnover (Day) | 48.418 Day | 46.566 Day | 50.026 Day | 79.408 Day | 6.913 Day |
| Remarks: | Real time quote last updated: 28/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB 116,808,000 |
| %Change | 11430.898% |
| EPS / (LPS) | RMB 0.050 |
| NBV Per Share (¥) | RMB 1.753 |